Johnson & Johnson and Merck Lead the Dow Healthcare Stock Rollercoaster Ride This Week

Johnson & Johnson (NYSE:JNJ): Current price $88.06

The J&J company Biosense Webster is announcing results from the SMART-AF IDE study on the safety and effectiveness of the Thermocool Smarttouch catheter 85.85 +0.09. the firm reported the 12-month safety and effectiveness results of the catheter and software module in the treatment of symptomatic, drug refractory, paroxysmal atrial fibrillation from the groundbreaking SMART-AF Investigational Device Exemption clinical trial. The 12-month study enrolled 172 subjects (72 percent male and 28 percent female) at 21 centers through out the United States. Thus far, the study attained its prospective safety and effectiveness endpoints with no unanticipated device-related adverse events, and 72 percent of subjects were free from AF recurrence at the close of the 12-month follow-up period.

The company has won United States approval to use its rheumatoid arthritis drug Simponi to treat patients suffering from a moderate to severe inflammatory bowel disease. The FDA on Wednesday approved the drug’s usage in adults having the chronic condition ulcerative colitis after conventional therapy has failed or continuous steroid use is required. Approximately 620,000 people in the United States have the disease, which leads to ulcers in the colon and rectum that cause abdominal pain and diarrhea, according to an FDA statement.

On Thursday, the orthopedic unit of Johnson & Johnson announced that it is phasing out production of all-metal replacement hips, reflecting an industry-wide movement to abandon the one-time widely used implants due to high early failure rates. In 2010, Johnson & Johnson’s DePuy Orthopaedics recalled an all-metal model called the Articular Surface Replacement, or A.S.R., as it was failing only a few years after implant. Artificial hips made from materials such as plastic and metal usually last 15 years or more prior to wearing out. However, after that recall, the firm continued to sell an all-metal version of a popular hip model called the Pinnacle, insisting that the all-metal product was safe and performing equally with other hip replacements, which position it reiterated on Thursday.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!


Don’t Miss: Is This Obamacare Provision a Threat to Food Companies?